Legend: Palais des congrès de Montréal = CC, Le Westin Montréal = W, Intercontinental Montréal = I
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 177 | Mon, 8/5/2013, 10:30 AM - 12:20 PM | CC-514b | |
| Statistical Methods in Oncology Trials and Studies — Contributed Papers | |||
| Biopharmaceutical Section , Biometrics Section , Section for Statistical Programmers and Analysts | |||
| Chair(s): Ying Wan, Janssen Research & Development | |||
| 10:35 AM | Assessing Methods for Dealing with Crossover in Active-Control Trials — Jihong Chen, Astellas ; Jay Yang, Astellas Pharma Global Development Inc. ; Xiaosha Sherman Zhang, Astellas Pharma Global Development, Inc. ; Andrew Strahs, AVEO | ||
| 10:50 AM | Continuous Longitudinal Tumor Measurement-Based Phase II Endpoints for Predicting Overall Survival (OS) Using the RECIST 1.1 Data Warehouse — Ming-Wen An, Vassar College ; Sumithra Mandrekar, Mayo Clinic ; Daniel J. Sargent, Mayo Clinic ; Xinxin Dong, University of Pittsburgh ; Axel Grothey, Mayo Clinic ; Jan Bogaerts, EORTC | ||
| 11:05 AM | Tumor Dynamics and Central-Review Bias in Progression-Free Survival Clinical Trials — Jonathan Siegel, Bayer HealthCare Pharmaceuticals | ||
| 11:20 AM | Study Designs in Induction/Maintenance Trials — Lixia Pei, Janssen Research & Development ; Kevin Liu, Janssen Reseach & Development | ||
| 11:35 AM | A Weighted Harrell-Davis Distance Test with Applications to Censored Data — Dongliang Wang, SUNY Upstate Medical University ; Alan D. Hutson , University at Buffalo | ||
| 11:50 AM | Identifying the Potential Risk Factors of Venous Thromboembolism Events in Clinical Trials — Kao-Tai Tsai | ||
| 12:05 PM | Meeting the Demand for More Sophisticated Study Designs: A Proposal for a New Type of Clinical Trial---The Hybrid Design — Guoxing (Greg) Soon, FDA ; Lei Nie, Food and Drug Administration | ||
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.